Cysteinyl Leukotriene Antagonist in Atherosclerosis Inhibition in Patients After Endovascular Treatment Due to Peripheral Arterial Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT04277702

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04277702
  • EudraCT 2020-000715-71
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04277702. Randomized; quadruple masking; primary purpose treatment. Start 2020-05 (anticipated); primary completion 2023-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cysteinyl Leukotriene Antagonist in Atherosclerosis Inhibition in Patients After Endovascular Treatment Due to Peripheral Arterial Disease
Acronym
CADET-PAD
Condition
Peripheral Arterial Disease
Condition
Peripheral Vascular Diseases
Condition
Lower Limb Ischemia
Condition
Atherosclerosis of Artery
Intervention (Drug)
Montelukast 10mg
Intervention (Procedure)
Endovascular treatment
Intervention (Drug)
Standard anti-platelet treatment
Lead sponsor
Jagiellonian University (class: other)

Record details

Record id
cardio:ct-nct04277702
Content hash
e327cb7e72b061c3ed9bdaef3c5cbca5a26ef396a1586805ff49b7def6629931